Skip to main content
padlock icon - secure page this page is secure

HIGH-DOSE CHEMOTHERAPY IN THE TREATMENT OF BREAST-CANCER

Buy Article:

$42.00 + tax (Refund Policy)

Dose is a critical determinant of the efficacy of chemotherapy. The dose response curve for virtually all anticancer agents is steep in both in vitro and in vivo experimental studies. However the application of the steep dose-response curve in the clinic has been troublesome for many years because of dose limiting bone marrow toxicity. Hematopoietic support with growth factors and/or peripheral stem cell transplantation now offers new possibilities to push doses up to levels where non-myeloid toxicity becomes dose limiting. Several trials applying high dose chemotherapy with stem cell support have been conducted in breast cancer. They showed a higher response rate and a higher percentage complete remissions compared with conventional treatment. Follow-up is short for most studies but some long-term complete remissions are reported. Developments in this field are reviewed.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: FREE UNIV AMSTERDAM HOSP,DEPT MED ONCOL,1007 MB AMSTERDAM,NETHERLANDS.

Publication date: April 1, 1995

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more